Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
RecruitingNot applicableNCT05780450
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia. As you can see, in the case of patients with Long Covid, we find several of these symptoms, so it is suggested that if transcranial direct current therapy (TDCS) gives such good results in relieving these symptoms, why couldn't it give such good results and help just as much in patients with Long Covid, since many of the symptoms are the same, even if the origin or cause is different.
Study details
- Official title
- Effectiveness of Transcranial Direct Current (tDCS) Treatment in Patients With Persistent Covid Who Present Headaches and Chronic Body Pain.
- Conditions
- Covid-19
- Long COVID
- Long Covid19
- SARS CoV 2 Infection
- Persistent COVID-19
- Migraine Disorders
- Headaches Chronic
- Cluster Headache
- Arthralgia
- Myalgia
- Chronic Pain
- Post-COVID-19 Syndrome
- Post COVID-19 Condition
- Sleep Quality
- Insomnia
- Interventions
- Device: Transcranial Direct Current Therapy (tDCS)
- Device: Sham (No Treatment)
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
- Start date
- 2023-04-01
- Primary completion
- 2026-11-05
- Sex
- All
- Age range
- from 16 Years
- Results posted
- No results posted in this snapshot
- Countries
- Spain
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with Persistent Covid * Men and women * All ages from 16 years old * Patients who passed the Covid in its acute phase in an asymptomatic, mild and severe way. Exclusion Criteria: * Patients without confirmation with positive PCR in the acute phase of Covid-19 * Patients with Persistent Covid who do not have at least one of these symptoms: migraines, headaches, chronic pain, neuropathic pain, arthralgia, myalgias * Patients with pacemaker / defibrillator * Patients with brain implants * Patients with cranial fractures * Pregnant
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05780450